Daniel Lorber

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

Josyf C. Mychaleckyj, Timothy E. Craven, Uma Nayak et al. · Diabetes Care · 2012 · 139 citations · Full text

SYNTAX Score and Long-Term Outcomes

Fumiaki Ikeno, Maria M. Brooks, Kaori Nakagawa et al. · Journal of the American College of Cardiology · 2017 · 84 citations

Syntax, Grammatical Formalism, Syntax Score +5

Responses to isoproterenol in a general population sample.

Daniel Lorber, Walter T. Kaltenborn, B BURROWS · PubMed · 1978 · 77 citations

Asthma, Endocrine Disruptors, Ventilation +12